Regeneron announced Monday that a single dose of its antibody cocktail reduces the risk of covid-19 disease by 81.6% for up to 8 months after administration, according to the results of an advanced clinical trial.
According to Myron Cohen, head of monoclonal antibody research for the prevention network funded by the US National Institutes of Health, Regeneron antibody therapy provides long-term immunity to covid-19.
The immunity is particularly important for immunocompromised individuals and those who do not respond to vaccines, the company said.
Treatment had shown in an earlier stage of the clinical trial a risk reduction of 81.4% in the first month after treatment.
During the 8-month evaluation period, there were no hospitalizations for covid-19 in the REGEN-COV group, but 6 such cases were recorded in the placebo group, Regeneron reported.
.
Source From: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
